Bringing neglected tropical diseases into the spotlight. by Payne, Lara & Fitchett, Joseph R
Nkurunungi, G; Lutangira, JE; Lule, SA; Akurut, H; Kizindo, R;
Fitchett, JR; Kizito, D; Sebina, I; Muhangi, L; Webb, EL; Cose, S;
Elliott, AM (2012) Determining Mycobacterium tuberculosis Infec-
tion among BCG-Immunised Ugandan Children by T-SPOT.TB and
Tuberculin Skin Testing. PLoS One, 7 (10). e47340. ISSN 1932-6203
Downloaded from: http://researchonline.lshtm.ac.uk/375705/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
Determining Mycobacterium tuberculosis Infection
among BCG-Immunised Ugandan Children by T-SPOT.TB
and Tuberculin Skin Testing
Gyaviira Nkurunungi1*, Jimreeves E. Lutangira1, Swaib A. Lule1, Hellen Akurut1, Robert Kizindo1,
Joseph R. Fitchett2, Dennison Kizito1, Ismail Sebina1, Lawrence Muhangi1, Emily L. Webb3,
Stephen Cose1,2, Alison M. Elliott1,2
1Co-infection Studies Programme, Medical Research Council/Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe, Uganda, 2Department of Clinical
Research, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3Department of Infectious Disease Epidemiology, London School of Hygiene and
Tropical Medicine, London, United Kingdom
Abstract
Background: Children with latent tuberculosis infection (LTBI) represent a huge reservoir for future disease. We wished to
determine Mycobacterium tuberculosis (M.tb) infection prevalence among BCG-immunised five-year-old children in Entebbe,
Uganda, but there are limited data on the performance of immunoassays for diagnosis of tuberculosis infection in children
in endemic settings. We therefore evaluated agreement between a commercial interferon gamma release assay (T-SPOT.TB)
and the tuberculin skin test (TST; 2 units RT-23 tuberculin; positive defined as diameter $10 mm), along with the
reproducibility of T-SPOT.TB on short-term follow-up, in this population.
Methodology/Principal Findings:We recruited 907 children of which 56 were household contacts of TB patients. They were
tested with T-SPOT.TB at age five years and then re-examined with T-SPOT.TB (n = 405) and TST (n = 319) approximately
three weeks later. The principal outcome measures were T-SPOT.TB and TST positivity. At five years, 88 (9.7%) children
tested positive by T-SPOT.TB. More than half of those that were T-SPOT.TB positive at five years were negative at follow-up,
whereas 96% of baseline negatives were consistently negative. We observed somewhat better agreement between initial
and follow-up T-SPOT.TB results among household TB contacts (k= 0.77) than among non-contacts (k= 0.39). Agreement
between T-SPOT.TB and TST was weak (k= 0.28 and k= 0.40 for T-SPOT.TB at 5 years and follow-up, respectively). Of 28
children who were positive on both T-SPOT.TB tests, 14 (50%) had a negative TST. Analysis of spot counts showed high
levels of instability in responses between baseline and follow-up, indicating variability in circulating numbers of T cells
specific for certain M.tb antigens.
Conclusions/Significance: We found that T-SPOT.TB positives are unstable over a three-week follow-up interval, and that
TST compares poorly with T-SPOT.TB, making the categorisation of children as TB-infected or TB-uninfected difficult.
Existing tools for the diagnosis of TB infection are unsatisfactory in determining infection among children in this setting.
Citation: Nkurunungi G, Lutangira JE, Lule SA, Akurut H, Kizindo R, et al. (2012) Determining Mycobacterium tuberculosis Infection among BCG-Immunised
Ugandan Children by T-SPOT.TB and Tuberculin Skin Testing. PLoS ONE 7(10): e47340. doi:10.1371/journal.pone.0047340
Editor: Madhukar Pai, McGill University, Canada
Received July 2, 2012; Accepted September 10, 2012; Published October 15, 2012
Copyright:  2012 Nkurunungi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by Wellcome Trust (www.wellcome.ac.uk) grant numbers 064693, 079110 and 086801. E. Webb was supported in part by the UK
Medical Research Council (www.mrc.ac.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gyaviira.nkurunungi@mrcuganda.org
Introduction
Worldwide, tuberculosis (TB) remains one of the most
important infectious causes of mortality. In 2010, there were an
estimated 8.8 million incident cases and approximately 1.4 million
people died from this disease [1]. Uganda is designated by the
World Health Organisation (WHO) to be one of the 22 high
burden countries for TB. A vast pool of individuals with latent
tuberculosis infection (LTBI) persists in developing countries,
posing a major barrier to global TB control [2]. The overall
lifetime risk of LTBI reactivation is approximately 5–10% among
older children and adults, but in infants and young children, the
risk of progression to active disease is increased; most disease cases
occur within 12 months of infection [3,4]. Moreover, infection in
childhood establishes the reservoir for future epidemics, making
proper diagnosis and treatment of LTBI in this vulnerable group
important for TB control [5].
For many years, the standard technique used to diagnose LTBI
has been the tuberculin skin test (TST). Although the TST has
proven to be useful in clinical practice, it has several known
limitations [3,6]. Perhaps the most significant of these is the cross
reactivity of the purified protein derivative of tuberculin used in
the TST with antigens from several nontuberculous mycobacteria,
and also with those from the Mycobacterium bovis bacille Calmette-
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Gue´rin (BCG) vaccine [7,8]. This means that the skin test may not
reliably discern LTBI from prior immunisation or infection with
other mycobacteria. Work done in the last decade has suggested
that in vitro T-cell based interferon gamma release assays (IGRAs)
may offer a suitable alternative approach to LTBI diagnosis [6,9].
One such assay is an Enzyme-linked immunosorbent spot
(ELISpot) assay, commercially known as T-SPOT.TB, whose
antigens (early secretory antigenic target 6, ESAT-6 and culture
filtrate protein 10, CFP-10) are coded by the Region of Difference
1 (RD1) genes of the Mycobacterium tuberculosis (M.tb) complex which
is absent from the majority of nontuberculous isolates, as well as
from BCG [7,10].
These immunoassays have been widely studied and reviewed in
adults and in contacts of infectious cases [3,9–17], yet very little
data exist about their performance in children from the general
population, and whether their diagnostic accuracy is superior to
that of TST, especially in endemic settings. In a recent systematic
review and meta-analysis, it was observed that IGRAs are less
sensitive and less specific in areas of high TB burden [18]. It is not
known whether IGRAs can replace TST surveys as a tool for
estimating the annual incidence of infection with M.tb. Lack of a
‘‘gold standard’’ reference test for LTBI has made it difficult to
assess performance of IGRAs, prompting adoption of surrogate
indicators such as evaluation of efficacy of preventive therapy
based on test results, predictive value of a test for active TB,
correlation with exposure gradient, sensitivity and/or specificity
among patients with active TB, and concordance between the
IGRA and other LTBI tests [19]. Some studies, mostly in adults,
have shown that after M.tb exposure, IGRA results fluctuate when
serial testing is done [14,20,21], and this has been attributed to
variations in laboratory procedures, within subject variability and
biological and environmental causes [22].
Within the structure of an existing study [23], we set out to
measure the prevalence of LTBI among BCG-immunised five-
year olds in Entebbe, Uganda, using the T-SPOT.TB assay. We
performed repeat T-SPOT.TB assays approximately three weeks
later to determine stability of responses, as well as the more
conventional TST to allow comparison with T-SPOT.TB results.
We present findings detailing T-SPOT.TB and TST test
agreement, stability of T-SPOT.TB responses on short-term
follow-up, and analysis of spot forming units in M.tb exposed
and unexposed children in a high prevalence African setting.
Methods
Study Design and Participants
This was an observational, cross sectional study. From March
2009 to April 2011, participants were prospectively recruited at
the fifth annual visit within the framework of the Entebbe Mother
and Baby Study (EMaBS), a population-based birth cohort in
Entebbe, Wakiso district, Central Uganda [23]. EMaBS was
originally established to evaluate the impact of maternal and
childhood helminth infections and of anthelminthic treatment on
immune responses to vaccines and childhood infections. The study
setting was an area with a moderately high background rate of TB:
unpublished data from the Uganda National TB and Leprosy
Programme (NTLP) indicates that 929 new pulmonary and extra-
pulmonary TB cases were detected in Wakiso district (estimated
population 1,205,000) in 2009, an incidence of 77 per 100,000.
Participants in EMaBS were enrolled at the Entebbe Hospital
antenatal clinic. Follow-up and enrolment into this sub-study of
TB infection was done at the EMaBS outpatient clinic within the
hospital grounds. Assessment of the household TB contacts, and
verification of the TB cases they were exposed to, was done at the
study clinic through verbal interviews of the children’s parents or
guardians. T-SPOT.TB assays were performed in the main
immunology research laboratory at the Uganda Virus Research
Institute, a five minute drive from the hospital. Demographic,
socioeconomic, and health-related information was collected
prospectively from enrolment through to follow-up at five years.
Participants were medically examined and anthropometric mea-
surements recorded. All the children were enrolled into the parent
study and into the T-SPOT.TB sub-study reported here following
informed and documented written consent by their parents or
formal guardian. Children were included in this sub-study if they
were five years of age, in good health and BCG-immunised. They
were excluded if they had moved outside the study area and could
not comply with the required procedures, or if the parent or
guardian did not give permission for the additional procedures
required for this study. Children enrolled in the larger EMaBS
study received BCG as neonates [24,25]: 94% of these immuni-
sations were given under observation at Entebbe Hospital, the
remainder were given elsewhere. Records were present at the
EMaBS study clinic. In the event of active disease or suspected TB
infection due to positive immunodiagnostic testing, they were
referred to a physician for medical examination, chest X-ray, and
treatment if required.
Our initial objective for the study was to estimate the prevalence
of LTBI in five year olds. At first we anticipated that T-SPOT.TB
could be used to accurately achieve this. For confirmation of the
results, and of the repeatability of the T-SPOT.TB test, the initial
protocol (Protocol 1) identified three groups of children to
undergo, in addition to T-SPOT.TB at age five years, a TST
and repeat T-SPOT.TB at follow-up three weeks later: 1) children
who were T-SPOT.TB-positive at 5 years, 2) children who were
reported to have had household contact with a TB patient, no
matter the initial test result, and 3) a comparison sample of
approximately 50 T-SPOT.TB-negative children, selected as the
first T-SPOT.TB-negative child, willing to undergo the additional
procedures, who was seen each week by the study doctor (SAL).
Once variations between the initial and repeat T-SPOT.TB results
from the same individuals became evident, it was clear that we
could not rely on the initial positive result to determine the
infection status of a child. The protocol was then amended and all
children who underwent the T-SPOT.TB test at five years were
asked to undergo the follow-up T-SPOT.TB and TST tests
(Protocol 2). By doing this, we hoped to determine whether
children with current LTBI could be identified by using T-
SPOT.TB as a screening assay, followed by confirmation with
repeat T-SPOT.TB combined with TST.
The study was approved by ethics committees of the Uganda
Virus Research Institute and London School of Hygiene and
Tropical Medicine, and by the Uganda National Council for
Science and Technology.
Procedures
T-SPOT.TB assays. Blood samples were processed within
eight hours of collection. The assays were carried out according to
the manufacturer’s instructions (Oxford Immunotec, Abingdon,
UK). Briefly, peripheral blood mononuclear cells were isolated by
centrifugation, washed twice and the cell concentration was
adjusted such that each of four wells of the assay plate contained
250,000 cells. The cells were stimulated for 16–20 hours (under
5% carbon dioxide at 37uC) with media (negative control),
phytohaemagglutinin (positive control) or peptides from the TB-
specific antigens ESAT-6 or CFP-10. The interferon gamma
released by single cells was observed as spots. Automated spot
counting was performed using an ELISpot plate reader (AID,
Tuberculosis Infection among Ugandan Children
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Strassberg, Germany). At the time of performing and reading the
assays, persons responsible for reading the test were blind to TST
results and other health related information.
Tuberculin skin tests. TST is unlikely to induce false
positive T-SPOT.TB responses [26], but might enhance sub-
threshold responses, so it was performed after drawing blood for
the repeat T-SPOT.TB assay at the follow-up study visit, three
weeks after the five-year visit. As recommended by the manufac-
turer, 2 tuberculin units of RT-23 purified protein derivative
(PPD) (Statens Serum Institut, Copenhagen, Denmark) were
injected intradermally into the forearm and the diameter of
induration was read 48–72 hours later. Tuberculin injections were
performed along the longitudinal axis of the forearm, and the
diameter of reaction was measured transversely. Reaction sizes
greater or equal to 10 mm were considered positive, based on
evidence from studies in Malawi that reactions of this size are
associated with increased risk of tuberculosis disease in both BCG-
immunised and non-immunised individuals, implying that these
individuals are latently infected with M.tb [27]. The team
performing the TSTs was trained by a highly experienced nurse.
Dual readings of a proportion of the TSTs (27.9%) were made by
two trained study nurses. The readings were made independently
by the two nurses and were not shown subsequently to either
reader. They showed a very close agreement between the readers:
there was a difference in induration in only two of the readings
and in both cases the difference was 1 mm. Because of this close
agreement, only the readings which were made by the first reader
will be included in our analysis. Tuberculin was kept under
refrigeration when not in use.
Data Analysis
Personal data and TST results were captured into Microsoft
Access databases. Data were double-entered and then checked
by the study data manager for integrity and consistency. Spot
counts were retrieved from the automated plate reader and
entered into Microsoft Excel. In accordance with the manufac-
turer’s instructions, T-SPOT.TB responses were considered
positive if either or both of panel A (containing ESAT-6
peptides) or panel B (containing CFP-10 peptides) had six or
more spot forming units (SFUs) above the negative control
when the negative control had five or less SFUs. In cases where
the negative control had six to 10 SFUs, the result was defined
as positive when either the ESAT-6- or CFP-10- stimulated well
contained at least twice as many SFUs as the negative control
well. The result was considered indeterminate if the positive
control had less than 20 SFUs (unless either panel A or panel B
was positive, as described above, in which case the result was
valid), or if the negative control well had 10 or more SFUs.
Data analysis was performed with STATA 10.0 (StataCorp,
College Station, Texas, USA). Concordance between baseline
and repeat T-SPOT.TB, and between T-SPOT.TB and TST
was calculated using the kappa (k) statistic, and assessed
according to the criteria suggested by Landis and Koch [28].
Strength of association between SFUs recorded for the two
RD1 antigens was estimated by calculating Spearman’s rank
correlation coefficient (rs). Proportions with positive TST results
were compared between groups defined by T-SPOT.TB results
using a chi-squared test. The chi-squared test was also used to
compare the number of participants for whom the two T-
SPOT.TB results agreed, and for whom T-SPOT.TB and TST
results agreed, between household contacts and non-household
contacts. A 5% significance level (two-sided p= 0.05) was used
for all tests.
Results
Characteristics of the Study Population
The Entebbe Mother and Baby Study (EMaBS) recruited 2507
pregnant women. Information was obtained on 2345 live births
and 1622 were under follow-up at five years, of whom 1438 were
seen by the study physicians at age five. Of these, 907 took part in
the T-SPOT.TB study. Of the 531 who did not take part in the
study, 186 had passed age five before the study began, the parents
or guardians of 237 did not give consent, and 108 had moved
outside the study area and could not comply with the required
procedures. Mothers of participants who took part in the T-
SPOT.TB study were on average older, more educated, and of
higher socio-economic status than mothers of those who were not
included in this study. The participants themselves were less likely
to be HIV infected than those who were not included in this study.
Of the 907 participants, 432 (47.6%) were female and 475 (52.4%)
were male. In total, 56 (6.2%) were household contacts of TB
patients, defined as being reported to have been in household
contact with a known TB case at any time during the past five
years. Analysis of anthropometric data showed a low level of
undernutrition, with prevalence of wasting (weight-for-height z-
score ,22) at 5.4%. Only 13 (1.4%) of the participants were HIV
infected, and prevalence of other infections was relatively low, with
4.0% of children having asymptomatic malaria infection and 9.6%
of children having a helminth infection. Where relevant, we
assessed the results from Protocol 1 (before amendment; 546
participants), and Protocol 2 (after amendment; 361 participants)
separately. The flow of participants in Protocol 1 and Protocol 2 is
shown in Figure 1 and Figure 2. The prevalence of wasting was
higher for children recruited under Protocol 1 compared to those
recruited under Protocol 2 (prevalence 7.6% versus 1.9%,
p= 0.001). The prevalence of HIV, asymptomatic malaria, and
any helminth infection did not differ between the two Protocols
(p = 0.92, 0.46 and 0.49, respectively). Only one child, among
those that were household TB contacts, or those that were T-
SPOT.TB and/or TST positive, was diagnosed with active TB.
T-SPOT.TB at Five Years and at Follow-up
Overall, at five years, 88 (9.7%) children were positive for T-
SPOT.TB, 770 (84.9%) were negative, and the remaining 49
(5.4%) were indeterminate. We re-examined 405 children at
follow-up approximately three weeks later (Figure 1 and Figure 2).
Excluding indeterminate results from both tests, 356 children were
eligible for direct comparison between the baseline and the repeat
T-SPOT.TB assay. For both protocols, agreement between T-
SPOT.TB at five years and T-SPOT.TB at follow-up was weak
(protocol 1, k=0.37; protocol 2, k=0.35). More than half of those
that were positive on the first test were negative on the second in
both protocols, whereas, excluding indeterminate results, 96% of
the baseline negatives were consistently negative at follow-up
(Figure 1 and Figure 2).
In order to ascertain whether spot counts were concentrated
around the diagnostic test cut-off level for participants whose T-
SPOT.TB result varied between age five and follow-up, we
analysed median changes in spot counts for each RD-1 antigen
according to whether participants were T-SPOT.TB positive on
the first test and negative on the second test (+/2) or T-SPOT.TB
negative on the first test and positive on the second (2/+) (Table 1).
Although some spot counts were close to the cut-off on the repeat
assay, many of the children who were either +/2 or 2/+ had
SFUs considerably above the cut-off for their positive test: the
median change in spot counts between the two tests ranged from
six to 17.5 SFUs.
Tuberculosis Infection among Ugandan Children
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Figure 1. T-SPOT.TB assay results at five years and at follow-up: Protocol 1.
doi:10.1371/journal.pone.0047340.g001
Figure 2. T-SPOT.TB assay results at five years and at follow-up: Protocol 2.
doi:10.1371/journal.pone.0047340.g002
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T-SPOT.TB and TST at Follow-up
Having demonstrated that variations between the initial and
repeat T-SPOT.TB results were not characteristic only of protocol
1, we combined results from both protocols to compare T-
SPOT.TB and TST results. Data for this analysis were therefore
biased towards children with a positive first T-SPOT.TB result,
and with a history of contact with a TB patient. Results from all
three tests (T-SPOT.TB at five years and at follow-up, and TST at
follow-up) were available for 319 children (Table 2). Agreement
between T-SPOT.TB and TST was weak (k=0.28 for T-
SPOT.TB assay at 5 years and k=0.40 for T-SPOT.TB at
follow-up). Combining T-SPOT.TB results, among children who
were negative on both T-SPOT.TB tests, 5 (2.2%) had a positive
TST; of those who were positive on only one T-SPOT.TB test, 4
(8.2%) had a positive TST; and of those who were positive on both
tests, 14 (50%) had a positive TST (p,0.001: Table 2). The 14
children who were positive on all three tests constituted only 4.4%
of the 319 children who had all three tests done.
We evaluated sizes of TST induration among children who had
differing T-SPOT.TB and TST results (Table 3), to establish
whether discordant results were associated with sizes close to the
10 mm cut-off. Children who were TST positive but T-SPOT.TB
negative at both time points tended to have TST indurations close
to the cut-off. By contrast, all but one of the 14 children who were
TST negative but T-SPOT.TB positive at both time points had no
detectable induration. Children who were T-SPOT.TB positive at
only one time point had large sizes of TST induration if they were
TST positive, but small or no detectable induration if they were
TST negative. These results paint a general picture that the high
level of disagreement between T-SPOT.TB and TST was not due
to threshold TST values.
Correlation between RD1 Antigens
To determine whether there was a correlation between ESAT-6
and CFP-10 RD1 antigens, we analysed spot counts in greater
detail (Figure 3). Correlation between ESAT-6 and CFP-10 spot
counts at five years was high (rs = 0.75), as was correlation at
follow-up (rs = 0.78). By contrast, correlation between ESAT-6
spot counts at five years and at follow-up was low (rs = 0.35), as was
correlation between CFP-10 spot counts at five years and at
follow-up (rs = 0.31). Thus, ESAT-6 and CFP-10 strongly corre-
lated with each other at a given time point, but each individual
antigen correlated poorly with itself at the two distinct time points.
This was also observed when analysis of spot counts was done
separately for each protocol (data not shown). These results
indicate that the same individuals were responding to both RD1
antigens at a given time point, but that different individuals were
responding at different time points. This was consistent with the
high levels of unstable responses observed between baseline and
follow-up.
Household Contacts of TB Patients
We enrolled 56 household contacts (HHC) of TB patients at five
years. Of these, 41 had a repeat T-SPOT.TB test at follow-up and
a TST result was available for 35. Excluding indeterminate results,
there was better agreement between initial and follow-up T-
SPOT.TB results among household TB contacts than among non-
contacts (k=0.77 and 0.39 respectively; p= 0.15): of those HHC
who were positive at five years, 70% were also positive at follow-
up, and all the HHC who were negative at five years were also
negative at follow-up. However, agreement between positive T-
SPOT.TB and TST was still weak: of the six HHC who were
positive on both T-SPOT.TB tests, only two had a positive skin
test. All the 27 HHC who were negative on both T-SPOT.TB tests
Table 1. Median difference in spot counts to ESAT-6 and CFP-10 for participants whose T-SPOT.TB result varied between age five
and follow-up.
T-SPOT.TB result Observations Median difference in SFUs IQR
Initial/follow-up
ESAT-6
Protocol 1 +/2 32 212.00 232.25, 24.00
2/+ 6 10.50 3.75, 13.50
Protocol 2 +/2 12 29.50 212.00, 27.25
2/+ 4 6.50 1.25, 11.00
CFP-10
Protocol 1 +/2 32 217.50 225.75, 28.50
2/+ 6 6.00 2.5, 17.75
Protocol 2 +/2 12 26.50 211.75, 23.00
2/+ 4 7.00 2.25, 11.00
SFUs: spot forming units; IQR: interquartile range; + indicates positive result; – indicates negative result.
doi:10.1371/journal.pone.0047340.t001
Table 2. Agreement between T-SPOT.TB and TST results.
TST result
T-SPOT.TB
result at 5
years
T-SPOT.TB
result
at follow-up – + Total
– – 218 (97.8%) 5 (2.2%) 223
– + 8 (88.9%) 1 (11.1%) 9
+ – 37 (92.5%) 3 (7.5%) 40
+ + 14 (50.0%) 14 (50.0%) 28
Indeterminate at either time
point
18 (94.7%) 1 (5.3%) 19
+ indicates positive result; – indicates negative result.
doi:10.1371/journal.pone.0047340.t002
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were also negative with the TST. Household TB contacts also
experienced somewhat higher proportions of T-SPOT.TB posi-
tivity (17.8% vs. 9.2%; p= 0.045 at baseline and 17.1% vs. 10.7%;
p= 0.265 at follow-up) and TST positivity (11.4% vs. 7.0%;
p= 0.353), than non-contacts. Age of first exposure was available
for 36 (64%) HHC. Five children were exposed as infants, two as
one-year olds, seven as three-year olds, five as four-year olds and
17 were exposed in the year preceding enrolment in this study.
Table 3. Assessment of size of TST in relation to T-SPOT.TB and TST results.
T-SPOT.TB result
at 5 years
T-SPOT.TB result at
follow-up TST result Number of children
Median size of TST
induration (mm) IQR
– – – 218 0.0 0.0, 0.0
– – + 5 11.0 10.0, 13.0
+ + + 14 15.0 13.7, 17.5
+ + – 14 0.0 0.0, 0.0
positive at either time point + 4 16.5 11.0, 19.7
positive at either time point – 45 0.0 0.0, 0.0
IQR: interquartile range; + indicates positive result; – indicates negative result.
doi:10.1371/journal.pone.0047340.t003
Figure 3. Association between RD1 antigens at five years and at follow-up. Results are presented as logs (to base 10) of spot forming units
for the two RD1 antigens. (a) ESAT-6 at five years vs.CFP-10 at five years (n = 179); rs = 0.7548 (b) ESAT-6 follow-up vs. CFP-10 follow-up (n = 158);
rs = 0.7838 (c) CFP-10 at five years vs. CFP-10 at follow-up (n = 127); rs = 0.3125 (d) ESAT -6 at five years vs. ESAT-6 at follow-up (n = 163); rs = 0.3576.
doi:10.1371/journal.pone.0047340.g003
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There was no evidence of a trend in probability of a positive test
result with age of exposure for T-SPOT.TB (p = 0.44 at
enrolment, p = 0.36 at follow-up) or for TST (p= 0.80).
Tuberculosis Infection Prevalence Estimates
The infection prevalence estimates by different measures are
shown in Table 4. A single T-SPOT.TB result at five years would
estimate infection prevalence at 9.7% among children in our
study, whereas a more stringent criterion of a positive TST and
positive T-SPOT.TB at both time points would put the prevalence
at 1.5%. From our data, the true infection prevalence in this
population of children lies somewhere between 1.5% and 11.2%,
highlighting the complexity of estimating LTBI in this age group
and setting, using T-SPOT.TB and/or TST.
Discussion
Our aim was to use the T-SPOT.TB assay to determine M.tb
infection prevalence among M.tb exposed and unexposed five year
old children in Entebbe, Uganda. We anticipated that positive
responses would be confirmed with a second T-SPOT.TB assay
and a TST. However, we have demonstrated a high level of
instability in positive T-SPOT.TB responses between baseline and
a three week follow-up and poor agreement between T-SPOT.TB
and TST responses, making the categorisation of children as LTB-
infected or LTB-uninfected difficult.
Analysis of SFUs showed that positive responses were not
concentrated around the diagnostic test cut-off level for children
whose T-SPOT.TB result varied between the first and second
tests. Instead, some children showed large changes in response –
both increases and decreases in SFUs – between the two
assessments. In contrast, ESAT-6 and CFP-10 spot counts
correlated well at each time point. Together these findings suggest
that our results may reflect a true change in the immune response
to the M.tb antigens in peripheral blood. Several other studies,
albeit with longer term follow-up, have observed variations in
responses between baseline and follow-up [14,21,29]. In a bid to
explain changes on follow-up when using IGRAs, Hill et al.
suggested that IGRA responses are not long-lived and generally
require sustained, continuous exposure to M.tb antigens to
maintain high frequencies [14]. They hypothesized that the
decline in response following exposure to M.tb may be a reflection
of the lifecycle of M.tb and the dynamic interaction with the host
immune system. As the mycobacteria enter a state of dormancy,
secretion of ESAT-6 and CFP-10 may decline leading to a
decrease in circulating memory T cells specific for the antigens
used in the assay [14,30]. The weak association between T-
SPOT.TB and TST in our study raises a further question as to
whether the responses observed indicate LTBI at all. It may be
that the unstable positive T-SPOT.TB responses in this young age
group reflect a weak (perhaps transient) response to M.tb antigens
in BCG-immunised children who resist the establishment of latent
infection. However, the short time between the two assessments in
our study make it unlikely that a change in TB exposure could
account for the effects observed.
Some studies have described a rather high rate of changes from
negative to positive IGRA response during follow-up in high-risk
populations in endemic settings [29,30]. Incident infections might
explain this, especially in studies involving contacts of TB patients,
or, again, the intermittent secretion of ESAT-6 and CFP-10 by
M.tb. However, in our study, changes from negative to positive
were very few compared to changes from positive to negative.
Fluctuation in IGRA results upon serial testing has sometimes
been attributed to technical factors. These factors may include
blood volume (for QuantiFERON assays), different staff perform-
ing the assay, preanalytical delays and reagents. The T-SPOT.TB
assay uses blood volumes as low as 2 ml; we collected 4 ml on
average. Most of the assays were performed by the study
laboratory technologists (GN and JEL), and any other staff
performing the assay were given specialist training and worked
under the supervision of the study laboratory technologists.
Doberne et al. [31] recently demonstrated that preanalytical delay
resulted in increased positive-to-negative reversions in as little as
six hours. Such delays were not characteristic of our study (median
time after sample collection= 1.4 hours, IQR 50 min-2.2 hours),
so time to processing is unlikely to explain our observed
fluctuations. A recent systematic review [20] showed that
tuberculin skin testing has a boosting effect on IGRA responses,
but this cannot explain the observed fluctuations in our study
because we drew blood before performing the TST.
Longitudinal assessments for IGRAs in published literature have
mainly been in contacts of TB patients [11,29,32,33]. Our study
investigated children, most of whom had no known TB contacts.
We hypothesize that the intense exposure that TB contacts
experience, compared to non-contacts, may explain the more
stable responses observed in those studies. In keeping with this
hypothesis, we found that household TB contacts in our study
showed better agreement between the baseline and repeat test
although the number of contacts was too small to provide good
power for sub-group analyses.
T-SPOT.TB has been dubbed the ‘‘100-year upgrade’’ to the
well-established TST for the diagnosis of TB infection [34].
Table 4. Mycobacterium tuberculosis infection prevalence estimates by different measures.
Measure of infection Number Prevalence estimate (95% CI)
Positive on all three tests (T-SPOT.TB at baseline and follow-up, TST at follow-up)* 14 1.5% (0.8%–2.6%)
Positive T-SPOT.TB result at either or both time points, and a positive TST** 18 2.0% (1.2%–3.1%)
Positive T-SPOT.TB result at both time points* 30 3.3% (2.2%–3.7%)
Positive T-SPOT.TB result at baseline 88 9.7% (7.9%–11.8%)
Any one positive T-SPOT.TB result** 98 10.8% (8.9%–13.0%)
Any one positive result (T-SPOT.TB or TST)** 102 11.2% (9.3%–13.5%)
The denominator is 907 for all the estimates.
*All but 9 of the baseline T-SPOT.TB positives were followed up. Prevalence doesn’t change when the 9 are subtracted from the denominator.
**Does not take into account the baseline T-SPOT.TB negatives that were not followed up, yet might have turned positive on follow-up. This is not likely to change the
prevalence estimates, since most (96%) of the baseline negatives that were followed up remained negative.
doi:10.1371/journal.pone.0047340.t004
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However, we report a high level of disagreement between the TST
and T-SPOT.TB in our cohort of children. Previous studies have
shown that levels of agreement are varied depending on the study
and outcome measurement. For example, in four investigations
that analysed agreement between the two tests, the k scores ranged
from -0.15 to 0.76 [16,35–37]. In our group, recent unpublished
data from adult women in Entebbe showed that T-SPOT.TB
performed better as an indicator of LTBI among adults. Among
23 women who tested T-SPOT.TB positive, 21 (91%) were TST
positive as well. All these findings support the perception that
agreement between the TST and the IGRA in the diagnosis of TB
infection might vary depending on several factors such as age,
history of previous BCG vaccination [38], and infection with other
mycobacteria.
The immunological inferences that can be drawn from the
observed discordance between T-SPOT.TB and TST in our study
are unclear. TST results may be falsely negative in children due to
the influence of factors such as malnutrition, concurrent viral and/
or parasitic infections, and concurrent medical conditions and
diseases [39]. However, these factors were not characteristic of our
participants. For example, we had TST data for six of the 13 HIV
positive participants, and none of these had discordant T-
SPOT.TB and TST results. The children in this study were
BCG-immunised, making it possible that the discordances
observed were due to false TST positives, but this is unlikely
because we observed fewer positives by TST than by T-SPOT.TB.
Furthermore, there was a general lack of intermediate sized TST
responses, which have been attributed to BCG vaccination and
infection with mycobacteria other than tuberculosis [40–42]. The
discordances may therefore be due to the unstable T-SPOT.TB
responses between baseline and follow-up, rather than a result of
the known shortcomings of the TST.
Tuberculin surveys carried out in the 1970s suggested that the
annual risk infection (ARI) with TB in Uganda was approximately
3%, although rates were lower than this in young children [43].
Recent national reports and other studies continue to quote this
estimate [44–47] although some surveys have indicated a steady
decline in ARI – for example, a survey in northern Uganda in
1994 estimated ARI at 1.4% [48]. Our results suggest that this
may now be a more realistic figure for young children in Central
Uganda also. However, our study cohort was derived from a small
area, and those who participated in this study showed some biases.
New M.tb infection surveys of broader scope may be warranted for
Uganda.
The principal limitation of our study was the change in
protocol, resulting in variation in sample sizes for T-SPOT.TB at
five years (n = 907), repeat T-SPOT.TB at follow-up (n= 405) and
TST (n= 319) making it difficult to compare the three tests
directly. Secondly, the proportions of children followed up were
different depending on the child’s T-SPOT.TB result at five years:
this was expected with Protocol 1 but not with Protocol 2, where
85.7% of the children who were initially positive were followed up
compared to 63.6% of those who were initially negative. Data
analysis was therefore biased towards children with a positive first
T-SPOT.TB result. We attempted to overcome this limitation by
presenting results from Protocol 1 and Protocol 2 separately where
it was relevant, and by comparing the participants’ characteristics
between the two protocols.
Our data provide a valuable insight into the usefulness of
IGRAs in the diagnosis of TB infection among children living in
endemic settings. It has been suggested that recommendations on
use of IGRAs in children younger than five years and in
immunocompromised children should be taken with caution
because of a lack of adequate published data on their efficacy in
these groups [49,50]. Our study has contributed to the increasing
evidence that IGRAs may not be superior to TST in children in
high incidence settings and cannot be used alone to diagnose TB
infection in these settings. Diagnosis of TB infection and
estimating TB infection prevalence among children in high
incidence settings remains a challenge; better diagnostic tests are
still needed.
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